Frontiers in cardiovascular medicineOct 15, 2026

GLP-1 Treatments for Obesity-Linked Heart Failure with Preserved Pumping Function: A Review Including Related Heart and Metabolic Studies

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 16, 2026

Abstract

The prevalence of obesity-related heart failure with preserved ejection fraction (HFpEF) is increasing.

Existing reviews of glucagon-like peptide-1 (GLP-1)-based therapies may lack methodological rigor.
Concerns exist regarding the independence of current evidence syntheses due to trial overlap.
This umbrella review focused on evaluating the quality and consistency of existing review-level evidence.

Simplified

The cardiometabolic phenotype of obesity-related heart failure with preserved ejection fraction (HFpEF) is increasing in clinical prevalence. Existing systematic reviews and meta-analyses have primarily summarized efficacy estimates for glucagon-like peptide-1 (GLP-1)-based therapies, but the credibility and independence of these syntheses remain uncertain because methodological limitations and overlap in primary trials have not been systematically evaluated. This umbrella review therefore appraised the methodological quality, overlap, consistency, and robustness of the existing review-level evidence rather than generating another efficacy synthesis.

Full Text

Full text is available at the source.

View Full Text ↗

GLP-1 Treatments for Obesity-Linked Heart Failure with Preserved Pumping Function: A Review Including Related Heart and Metabolic Studies

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief